ESPR

Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C). The company has developed oral non-statin LDL-C lowering medicines for patients who cannot achieve their cholesterol goals with statins alone or who are statin-intolerant. Esperion's commercial products provide additional treatment options for managing cardiovascular risk through lipid modification. The company continues to conduct clinical research to expand approved indications and develop next-generation cardiovascular therapies.